Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Income from Continuing Operations (2020 - 2025)

Barinthus Biotherapeutics' Income from Continuing Operations history spans 6 years, with the latest figure at 11103000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 46.08% year-over-year to 11103000.0; the TTM value through Dec 2025 reached 66458000.0, down 8.62%, while the annual FY2025 figure was 66458000.0, 8.62% down from the prior year.
  • Income from Continuing Operations reached 11103000.0 in Q4 2025 per BRNS's latest filing, up from 14571000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 15689000.0 in Q2 2022 to a low of 23824000.0 in Q2 2023.
  • Average Income from Continuing Operations over 5 years is 12181300.0, with a median of 16119000.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 248.69% in 2022, then tumbled 807.96% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 16718000.0 in 2021, then dropped by 26.59% to 21163000.0 in 2022, then rose by 18.3% to 17290000.0 in 2023, then dropped by 19.09% to 20591000.0 in 2024, then soared by 46.08% to 11103000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Income from Continuing Operations are 11103000.0 (Q4 2025), 14571000.0 (Q3 2025), and 21126000.0 (Q2 2025).